Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa

Study Identifier:
D8590C00004
ClinicalTrials.gov Identifier:
NCT06079372
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Recruitment Complete

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: ALXN1850
  • Drug: asfotase alfa
Date
Apr 2024 - Aug 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 2 - 11 Years
Requirements Information
Sex
Female & Male
Age
2 - 11 Years

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: ALXN1850
  • Drug: asfotase alfa
Date
Apr 2024 - Aug 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 2 - 11 Years years
Requirements Information

Protocol Summary

The primary purpose of this study is to assess the safety and tolerability of ALXN1850 versus asfotase alfa in pediatric participants with HPP previously treated with asfotase alfa.

Trial Locations

Location
Status
Location
Research Site
Hartford, Connecticut, United States, 06106
Status
N/A
Location
Research Site
Baltimore, Maryland, United States, 21287
Status
N/A
Location
Research Site
Minneapolis, Minnesota, United States, 55455
Status
N/A
Location
Research Site
Kansas City, Missouri, United States, 64108
Status
N/A
Location
Research Site
Durham, North Carolina, United States, 27705
Status
N/A
Location
Research Site
Nashville, Tennessee, United States, 37212
Status
N/A